The UK is set to become a leader in reducing the environmental impact of asthma treatments with the approval of lower-carbon inhalers for millions of patients. The Medicines and Healthcare products Regulatory Agency (MHRA) has given its green light to new versions of the Clenil Modulite 100 micrograms and 200 micrograms inhalers, which contain beclometasone dipropionate – a corticosteroid that helps reduce airway inflammation and prevent asthma symptoms.
These devices are prescribed for the ongoing management of asthma in both adults and children across the UK. This significant announcement marks a global first, as these are the initial pressurised metered-dose inhalers (pMDI) worldwide to receive authorisation for using the next-generation propellant, HFA-152a. This innovative propellant is designed to reduce the environmental impact of the inhalers while ensuring the active medicine is delivered effectively.
The MHRA's decision is underpinned by robust evidence demonstrating that the new formulations perform comparably to the existing authorised products. This ensures that the high standards of quality, safety, and clinical benefit that patients expect are maintained. Julian Beach, MHRA Executive Director of Healthcare Quality and Access, highlighted the importance of this approval, stating that it demonstrates how innovation can support both patient care and environmental sustainability.
Asthma is a prevalent long-term respiratory condition affecting millions in the UK, characterised by symptoms such as wheezing, coughing, chest tightness, and shortness of breath. According to NHS data, around 5.4 million people in the UK are currently receiving treatment for asthma, including 1.1 million children. Inhalers like Clenil Modulite are crucial for managing the condition and preventing severe exacerbations.
The new, lower-carbon versions of the inhalers are anticipated to become available in the UK later in 2026. Until then, current versions of Clenil Modulite will continue to be supplied to patients. As with all medicines, the MHRA will continue to closely monitor the safety and effectiveness of these new inhalers. Patients experiencing any suspected side effects should consult their doctor, pharmacist, or nurse, and report them via the Yellow Card scheme.